European Journal of Heart Failure最新文献

{"title":"Sexual dimorphism in the relationships between intramyocardial fat, myocardial fibrosis, and exercise intolerance in heart failure with preserved ejection fraction.","authors":"Arnold C T Ng, Xin Dong, Katlyn E Koepp, Masaru Obokata, Hidemi Sorimachi, Graham Galloway, Philip Araoz, Victoria Delgado, Jeroen J Bax, Barry A Borlaug","doi":"10.1002/ejhf.3473","DOIUrl":"https://doi.org/10.1002/ejhf.3473","url":null,"abstract":"","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":" ","pages":""},"PeriodicalIF":16.9,"publicationDate":"2024-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142306793","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sex differences in cardiac structure and function following acute myocardial infarction: Insights from the PARADISE-MI echocardiographic substudy.","authors":"Xiaowen Wang, Maria A Pabon, Maja Cikes, Karola Jering, Wilfried Mullens, Lars Kober, Pardeep S Jhund, Attila Kovacs, Bela Merkely, Yinong Zhou, John J V McMurray, Amil M Shah, Sheila M Hegde, Brian Claggett, Marc A Pfeffer, Scott D Solomon","doi":"10.1002/ejhf.3472","DOIUrl":"10.1002/ejhf.3472","url":null,"abstract":"<p><strong>Aims: </strong>The incidence of heart failure hospitalization is higher in women than in men after myocardial infarction (MI). Sex-related differences in left ventricular (LV) remodelling may contribute to the differences in post-MI outcomes. The aim of this study was to assess sex differences in echocardiographic parameters post-MI, and whether the relationship between echocardiographic parameters and clinical outcomes differs by sex.</p><p><strong>Methods and results: </strong>In the PARADISE-MI trial, patients were randomized to sacubitril/valsartan or ramipril within 0.5 to 7 days of high-risk MI. In the pre-specified echocardiographic substudy, 544 patients underwent echocardiography at the time of randomization and after 8 months. We compared key echocardiographic parameters in men and women and their association with primary composite outcome (cardiovascular death or incident heart failure). At baseline, women had higher LV ejection fraction (LVEF), lower LV end-diastolic volume (LVEDV) index, LV end-systolic volume (LVESV) index, and LV mass index. After adjusting for baseline clinical differences, changes in these echocardiographic parameters from baseline to 8 months were not significantly different in women versus men. Lower LVEF, higher LVEDV, LVESV, left atrial volume index, and average E/e' were associated with a higher risk of the primary composite outcome. Sex did not modify the relationship between echocardiographic parameters and clinical outcome.</p><p><strong>Conclusions: </strong>Despite baseline differences in measures of cardiac function between men and women following acute high-risk MI, there were no significant sex-related changes in chamber size or LV function. Sex did not modify the association between echocardiographic parameters and clinical outcome.</p>","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":" ","pages":""},"PeriodicalIF":16.9,"publicationDate":"2024-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142306792","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Translating the 2021 ESC heart failure guideline recommendations in daily practice: Results from a heart failure survey. A scientific statement of the ESC Council for Cardiology Practice and the Heart Failure Association of the ESC","authors":"Ruxandra Christodorescu, Oliviana Geavlete, Marc Ferrini, Thomas Kümler, Konstantinos Toutoutzas, Antoni Bayes-Genis, Petar Seferovic, Marco Metra, Ovidiu Chioncel, Giuseppe M.C. Rosano, Gianluigi Savarese","doi":"10.1002/ejhf.3444","DOIUrl":"https://doi.org/10.1002/ejhf.3444","url":null,"abstract":"Real-world data show that guidelines are insufficiently implemented, and particularly guideline-directed medical therapies (GDMT) are underused in patients with heart failure and reduced ejection fraction (HFrEF) in clinical practice. The Council for Cardiology Practice and the Heart Failure Association of the European Society of Cardiology (ESC) developed a survey aiming to (i) evaluate the perspectives of the cardiology community on the 2021 ESC heart failure (HF) guidelines, (ii) pinpoint disparities in disease management, and (iii) propose strategies to enhance adherence to HF guidelines.","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":"73 1","pages":""},"PeriodicalIF":18.2,"publicationDate":"2024-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142317194","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Add-on rituximab for primary heart involvement associated with systemic sclerosis: A step forward in the tailored treatment of myocarditis?","authors":"Maria De Santis, Antonio Tonutti, Francesca Motta, Stefano Rodolfi, Lorenzo Monti, Federica Catapano, Marco Francone, Carlo Selmi","doi":"10.1002/ejhf.3467","DOIUrl":"https://doi.org/10.1002/ejhf.3467","url":null,"abstract":"","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":" ","pages":""},"PeriodicalIF":16.9,"publicationDate":"2024-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142306789","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predicting survival after Impella implantation in patients with cardiogenic shock: The J-PVAD risk score","authors":"Toru Kondo, Tomo Yoshizumi, Ryota Morimoto, Takahiro Imaizumi, Shingo Kazama, Hiroaki Hiraiwa, Takahiro Okumura, Toyoaki Murohara, Masato Mutsuga","doi":"10.1002/ejhf.3471","DOIUrl":"https://doi.org/10.1002/ejhf.3471","url":null,"abstract":"Impella has become a new option for mechanical circulatory support in patients with cardiogenic shock (CS); however, prognostic models for patients after Impella are lacking. We aimed to identify the factors that predict in-hospital mortality in patients with CS requiring Impella and develop a new risk prediction model.","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":"8 1","pages":""},"PeriodicalIF":18.2,"publicationDate":"2024-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142247137","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Aetiology and clinical manifestations of patients with non-dilated left ventricular cardiomyopathy.","authors":"Emanuele Monda,Anna Murredda,Marta Rubino,Gaetano Diana,Giuseppe Palmiero,Federica Verrillo,Chiara Cirillo,Annapaola Cirillo,Adelaide Fusco,Giulia Frisso,Martina Caiazza,Giuseppe Limongelli","doi":"10.1002/ejhf.3470","DOIUrl":"https://doi.org/10.1002/ejhf.3470","url":null,"abstract":"","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":"199 1","pages":""},"PeriodicalIF":18.2,"publicationDate":"2024-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142273418","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"In-hospital course of patients with heart failure with improved ejection fraction in the DELIVER trial","authors":"Maria A Pabon, Muthiah Vaduganathan, Brian L. Claggett, Safia Chatur, Sara Siqueira, Pablo Marti-Castellote, Rudolf A. de Boer, Adrian F. Hernandez, Silvio E. Inzucchi, Mikhail N. Kosiborod, Carolyn S.P. Lam, Felipe Martinez, Sanjiv J. Shah, Akshay S. Desai, Pardeep S. Jhund, John J.V. McMurray, Scott D. Solomon, Orly Vardeny","doi":"10.1002/ejhf.3410","DOIUrl":"https://doi.org/10.1002/ejhf.3410","url":null,"abstract":"Patients with heart failure (HF) with improved ejection fraction (HFimpEF) may face residual risks of clinical events that are comparable to those experienced by patients with HF whose left ventricular ejection fraction (LVEF) has consistently been above 40%. However, little is known about the clinical course of patients with HFimpEF during hospitalization for HF.","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":"10 1","pages":""},"PeriodicalIF":18.2,"publicationDate":"2024-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142247140","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Aficamten in non‐obstructive hypertrophic cardiomyopathy: Unlocking new horizons?","authors":"Maddalena Rossi, Enrico Fabris, Gianfranco Sinagra","doi":"10.1002/ejhf.3461","DOIUrl":"https://doi.org/10.1002/ejhf.3461","url":null,"abstract":"","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":"33 1","pages":""},"PeriodicalIF":18.2,"publicationDate":"2024-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142236203","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Myeloperoxidase: Reviving an old ally for immunomodulation in heart failure?","authors":"Gabriela M Kuster,Birgit Assmus,Felix Mahfoud","doi":"10.1002/ejhf.3468","DOIUrl":"https://doi.org/10.1002/ejhf.3468","url":null,"abstract":"","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":"64 1","pages":""},"PeriodicalIF":18.2,"publicationDate":"2024-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142245389","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reply to the letter regarding the article ‘Sodium–glucose cotransporter 2 inhibitors influence skeletal muscle pathology in patients with heart failure and reduced ejection fraction’","authors":"Nathanael Wood,&nbsp;Klaus K. Witte,&nbsp;T. Scott Bowen","doi":"10.1002/ejhf.3442","DOIUrl":"10.1002/ejhf.3442","url":null,"abstract":"&lt;p&gt;We are grateful for the important and timely comments of Stöllberger and colleagues about our study on the effects of sodium–glucose cotransporter 2 inhibitors (SGLT2i) on skeletal muscle in people with heart failure and reduced ejection fraction (HFrEF).&lt;span&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/span&gt; We agree entirely that further research is required to understand the effects of these agents on skeletal muscle structure and function, especially in older people.&lt;/p&gt;&lt;p&gt;In response to their comments, one of the unique features of our work is that the sample collection spanned the approval and guideline uptake of these agents in people with HFrEF. This allowed us, albeit in a longitudinal manner, to compare people treated with and without these agents. As reassurance, it is standard practice in our laboratory to keep the (anonymized, coded) samples separate from the clinical data until terminal analysis, which ensures no bias. This approach, the longitudinal sample collection, and the requirement of guideline-directed medical therapy prior to device therapy, comes with both benefits and challenges since, as highlighted, some baseline characteristics such as age, N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels and prevalence of atrial fibrillation were numerically higher (but not significantly different) between our groups. However, the standard deviations showed a wide distribution (age 73 ± 9 vs. 66 ± 10 years; NT-proBNP 4052 ± 4813 vs. 2039 ± 2526 ng/L), highlighting the overlap between groups and, in the absence of any correlation with age, this is unlikely to be a confounding factor. Finally, we combined human with highly-controlled experiments in a mouse model to independently confirm the favourable effects of SGLT2i on muscle pathology.&lt;/p&gt;&lt;p&gt;Stöllberger and colleagues point out that we did not have a definitive diagnosis of the aetiology of HFrEF in all patients, enquired whether all patients underwent a formal neurology consult, and propose that we describe all types and doses of medications. In response, we would propose that since the aetiology of HFrEF in a patient without angina has little bearing on treatment, invasive coronary angiography or cardiac magnetic resonance in older people with HFrEF is not routine. Moreover, we also do not routinely refer patients with HFrEF to neurology to exclude neuromuscular disease in the absence of symptoms or signs. Finally, we would like to reassure Stöllberger and colleagues that, as required prior to prescription of an implantable device for HFrEF, patients were taking optimally tolerated doses of guideline-directed medical therapy with no differences in doses across groups.&lt;/p&gt;&lt;p&gt;We agree entirely that the addition of global muscle mass or functional strength assessments would have added valuable insight into the effect of SGLT2i in HFrEF. While a direct muscle biopsy at a single site comes with both advantages and limitations, we would like to point out that volitional strength and imaging assessment","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":"26 11","pages":"2474-2475"},"PeriodicalIF":16.9,"publicationDate":"2024-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/ejhf.3442","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142245600","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}